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Introduction 
The safety/efficacy ratio, or therapeutic ratio, of an anti- 
asthmatic agent is determined by the relationship between 
its dose-response relationship for anti-asthmatic clinical 
efficacy and its systemic adverse effects (1). An under- 
standing of the relative risks and benefits of any anti- 
asthmatic agent are vital in order to fully appreciate how 
the agent should be used optimally in everyday clinical 
practice. 
Anti-asthmatic efficacy can be measured through the use 
of recognized laboratory or domiciliary clinical endpoints 
(such as FEV,, FEFzs~soh, AM PEF). However, safety has 
to be measured through perhaps a more subtle interaction 
of pharmacological and pharmacokinetic parameters, 
combined with clinically relevant endpoints such as adverse 
events, as well as biochemical, haematological and labora- 
tory markers. 
Whilst an understanding of the safety/efficacy ratio of 
any agent per se is important, it is perhaps of more value to 
understand its therapeutic index relative to other available 
anti-asthmatic agents, in order that the physician might 
choose the optimal therapy for each individual patient. The 
aim of this paper is therefore to discuss the relative 
comparative safety/efficacy ratio of QVARTM (3M Phar- 
maceuticals, St Paul, MN, U.S.A.) [hydrofluoroalkane- 
134a beclomethasone dipropionate (HFA-BDP)] in com- 
parison with other anti-asthmatic preparations, by looking 
at the influence of pharmacokinetic and pharmacological 
factors, device factors, efficacy factors and safety con- 
siderations on this parameter. 
Relative efficacy of HFA-BDP 
The HFA-BDP dose ratio for equipotent efficacy can be 
summarized in the following table (Table I). These data 
show that switching from a chlorofluorocarbon (CFC)- 
BDP formulation to HFA-BDP increases the delivery of 
beclomethasone resulting in a 2:l comparative dose ratio. 
In contrast, HFA-BDP has a I:1 comparative dose ratio 
compared to fluticasone CFCpMD1, a result of (a) 
fluticasone showing twice the level of receptor potency 
and affinity compared to beclomethasone dipropionate [and 
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its active metabolite beclomethasone-l7-monopropionate 
(IFBMP)] and (b) HFA-BDP demonstrating twice the 
delivery compared to fluticasone pMDI-CFC. 
Finally, budesonide and BDP have approximately the 
same receptor potency, but as the HFA inhaler delivers 
approximately twice that of the budesonide turbohaler, 
there is a resultant potency of 2:l. 
Relative safety of 
DEVICE FACTORS 
HFA-BDP 
The reformulation of beclomethasone from a CFC-based 
formulation into an HFA-formulation in QVARr”, 
together with improvements in inhaler device technology, 
have resulted in an extrafine mean particle size, which has 
allowed improved delivery of BDP into the large and small 
airways. This has resulted not only in the improved efficacy 
discussed previously in this supplement, but also in 
improvements in the physical characteristics of the aerosol 
plume, producing a warmer and gentler spray compared to 
fluticasone pMDI-CFC (2). Thus, the cold freon effect may 
be reduced through a combination of reformulation and 
device technology. This could conceivably translate into 
improved patient compliance and better lung delivery, 
because of the lower tendency for gagging due to the cold 
freon impaction on the posterior oropharynx. 
PHARMACOLOGICAL AND 
PHARMACOKINETIC FACTORS 
Plnsmlz eh+zntion _ 
Lipophilic substitutions of the basic glucocorticosteroid 
nucleus affects the volume of distribution and hence the 
degree of retention within the systemic tissues (3). For 
example, fluticasone and mometasone furoate are very lipid 
soluble; in contrast triamcinolone acetonide, budesonide 
and I7-BMP have a much lower level of lipid solubility 
(Fig. 1). 
Drugs with high lipid solubility are found at a relatively 
low level in the blood (as blood is mainly water) and at a 
relatively high level in systemic tissue (as tissue is mainly 
fat). In contrast, compounds which are much less lipid 
soluble have a relatively higher concentration in the blood as 
compared to the systemic tissue. This will be reflected in the 
total volume of distribution (i.e. blood and systemic tissue) 
which will be much higher for fluticasone than 1 ‘I-BMP. 
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TABLE 1. HFA-BDP dose ratio for equipotent efficacy 
Inhaled steroid formulation HFA-BDP fig- 
equipotent efficacy 
dose ratio 
CFC-BDP (QVAR) 
Fluticasone-CFC pMD1 (Flixotide) 
Budesonide-DPI (Pulmicort) 
2:l 
1:l 
2:l 
This difference is important when calculating systemic 
absorption or total bioavailability. For example, if a blood 
sample is used to measure the systemic exposure of 
fluticasone, a falskly low value will result because the 
bioavailability will have been measured in the wrong 
compartment. This is because fluticasone propionate has 
the highest level of lipophilicity amongst the currently 
available inhaled corticosteroids, which may account for it 
having a relatively long elimination half-life (14.4h) (3) 
(Table 2). This is because there is constant equilibrium 
between the blood and tissue compartments at steady-state, 
with the tissue acting, in effect, as a biological slow release 
reservoir. An analogy is to think of a wet sponge with the 
drip representing the intravascular drug, and the total 
systemic exposure representing what comes out when 
squeezing the sponge. 
Although drugs such as 17-BMP triamcinolone acetonide 
and budesonide have relatively high plasma levels (due to a 
small volume of distribution), they tend to have much 
High total volume of distribution 
(i.e. iotra + extra vascular) 
l +++ lipid soluble + lipid soluble 
(e.g. W l (e.g. 17-BMP) 
0 Extravasclllar >>> Intmvascular 
~63 
Intravascular 
compartment 
shorter half-lives (between 2-6 h) (3-8) as they do not 
equilibrate with systemic tissue to the same degree. 
Drug accumulation in blood and tissue occurs when 
fluticasone proprionate is administered twice daily, because 
its elimination half-life (14.4 h) is longer than the 12-h 
dosing interval (9). 
Plzartnacokinefics 
Whilst plasma elimination half-lives can give valuable 
information regarding drug accumulation, such data need 
to be confirmed through single and multiple dose pharma- 
cokinetic studies, especially as the improved delivery of 
HFA-BDP to the lungs (with less swallowed) could affect 
the absorption of BDP. As can be seen from Fig. 2 (IO), as 
the level of a single dose of HFA-BDP increases from 100 
to 400 pg there is a linear increase in serum concentration of 
beclomethasone alcohol. In particular the maximum con- 
centration (C,,,&-a good surrogate for the lung dose due 
to the very rapid absorption of the drug from the lung into 
the blood-doubles with doubling of the dose. 
With repeated dosing, at steady-state, the serum profile 
of total beclomethasone from HFA-BDP is very similar to 
that from single-doses, with the C,,, again being propor- 
tional to the dose. In addition, such multiple dosing to 
steady-state indicates that very little accumulation of 
beclomethasone occurs (the accumulation ratio between 
single and repeated dosing is 1*3), especially when this is 
compared to fluticasone studies, which suggest an accumu- 
lation ratio of approximately three-fold (3). 
Low total volume of distribution 
. Intravascular >>> Extravascuhr 
I Intmvascular @c compartment 
FIG. 1. Schematic diagram to illustrate intravascular vs. extravascular distribution with steady-state inhaled corticosteroid. 
FP: fluticasone propionate; 17-BMP: beclomethasone-17-monopropionate. 
TABLE 2. Plasma elimination half-life for inhaled steroids 
Inhaled steroid formulation TI/Z (h) 
Fluticasone propionate 14.4 
Beclomethasone 17-monopropionate 6.5 
Triamcinolone acetonide 2.5 
Budesonide 2.3 
Flunisolide 1.6 
Source: Refs 3,5-K 
SYSTEMIC SIDE-EFFECTS 
Adrenal suppression 
The administration of exogenous inhaled corticosteroids 
results in a negative feedback on glucocorticoid receptors in 
the hypothalamus and anterior pituitary gland, which in 
turn suppresses levels of corticotropin-releasing hormone 
and corticotropin, respectively, with a consequent reduc- 
tion in endogenous cortisol secretion from the adrenal cortex. 
Adrenocortical function can be assessed mainly in two 
ways, either through screening tests of basal adrenocortical 
activity, or through dynamic stimulation tests which 
evaluate impaired adrenal reserve (11). Some of these are 
more practical than others (Table 3). 
Prolonged suppression of corticotropin levels eventually 
results in atrophy of the adrenal cortex, which may become 
clinically relevant if the source of exogenous corticosteroid 
is stopped suddenly, or if there is an acutely stressful event 
whereby the adrenal cortex is unable to generate an 
adequate cortisol response (1). 
Single dose 
day 1 (dose 1) 
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For example, the most sensitive way to evaluate basal 
diurnal adrenocortical activity is to perform a 24-h 
integrated measurement of plasma cortisol levels or urinary 
free cortisol excretion (11). However, these are impractical 
in a routine, outpatient environment, and are generally only 
used in the research laboratory. For this reason more 
practical methodologies are usually employed, such as the 
measurement of fractionated overnight or early morning 
urinary cortisol corrected for creatinine excretion (12,13), 
which has been shown to be as sensitive as an integrated 
24-h urinary free cortisol collection. 
Plasma cortisol 
In everyday practice it is more relevant to consider 
individual data rather than mean responses. These data 
show that even at the highest dose of HFA-BDP 
(800pgday-‘) less than 5% of the patients showed an 
abnormally low AM cortisol value (Fig. 4). This would 
The effect of HFA-BDP on the hypothalamic-pituitary- 
adrenal (HPA)-axis has been addressed in a meta-analysis 
of AM plasma cortisol effects. Figure 3 shows the 
regression lines of identity for HFA-BDP and CFC-BDP 
in which the HFA-BDP data has been extrapolated above 
the 800pgday-’ dose, because this is the highest dose of 
HFA-BDP which has been evaluated and represents the 
maximum licensed dose. As can be seen, there is a dose- 
response effect for adrenal suppression with both HFA- 
BDP and CFC-BDP, with no statistical difference between 
the two lines of identity. Reassuringly, there is no 
suppression of the mean AM plasma cortisol values up to 
the maximum dose of 800pgday-’ of HFA-BDP. These 
results are supported by individual data from Gross et al. 
and Davies et al. (14,15) (Fig. 4). 
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FIG. 2. Serum total beclomethasone alcohol. Source: 
4oopg; -: CFC-BDP 400 pg. 
Ref. 10.. . . : HFA-BDP 100 pg; -: HFA-BDP 200 pgg; --: HFA-BDP 
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TABLE 3. Tests for effect on HPA-axis 
Test Sensitivity Practicality 
250 pg ACTH stimulation 
Overnight urinary cortisol 
24 h urinary cortisol 3 X 
24 h serum cortisol 
’ 
J 
8 AM serum cortisol IX 
-50 1; ’ 
I I , I I I 
200 400 600 800 1000 1200 1400 1600 
Dose (a day-‘) 
Fro 3. Dose response of % suppression of AM cortisol 
(meta-analysis of four studies). 0: HFA-BDP (n =478); 
0: CFC-BDP (n = 300). 
20 r P< 0.05 I I 
HFA-BDPCFC-BDPHFA- HFA-BDP CFC-BDP 
4OOpg 800,ug placebo 8001~ 1500~8 
&-CJSS et al., Chest 1998 Davies et al., Respir Med 1998 
FIG. 4. Percentage of patients with AM cortisol values 
below reference range (week 12). Source: Ref. 17. 
suggest that at the doses used in these studies, HFA-BDP 
has little or no effect on morning plasma cortisol levels and 
hence, by implication, no effect on the HPA-axis. Indeed, 
on a pg for pg basis, up to 8OOpg, there would seem to be 
no difference between HFA-BDP and CFC-BDP in terms 
of HPA-axis function. 
Urinary cortisol 
In a meta-analysis of 21 studies of urinary cortisol (24 h or 
overnight) levels, Lipworth (16) showed that Auticasone 
exhibited a significantly steeper dose-related systemic 
bioactivity than beclomethasone (l-9-fold; P< 0*05), 
triamcinolone acetonide (3.7-fold; P < 0.05) or budesonide 
Beclomethasone 
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FIG. 5. Dose-response of 24 h or overnight urinary cortisol 
(meta-analysis of 21 studies). Source: Ref. 16. 
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FIG. 6. Elfect of HFA-BDP on urinary free cortisol 
excretion - percentage change from baseline. Source: 
Ref. 17. 
(4.3-fold; PcO.001) (Fig. 5), although there were no 
significant differences between beclomethasone, budesonide 
or triamcinolone. In the studies analysed, all the inhaled 
steroids were used within the recommended dosing range 
(up to 2mgday-‘) and all produced dose-related adrenal 
suppression. 
This dose-response effect on urinary cortisol was also 
seen by Thompson Ed al. (17) with HFA-BDP (Fig. 6). In 
this ICday, dose level blind, randomized, parallel group 
study, patients with mild asthma were randomized into five 
treatment groups (placebo, HFA-BDP 200, 400 and 
800 pg day-‘; CFC-BDP 8OOpg day-‘) and the relative 
effect on 24-h urinary free cortisol (UFC) assessed. As can 
be seen,’ there was a shallow dose-dependent fall in 24-h 
UFC excretion with increasing doses of HFA-BDP. The 
mean percentage change in 24-h UFC excretion with HFA- 
BDP 200 pg day-’ was not significantly different to that 
obtained with HFA-placebo, with there being no clinically 
significant differences at the other HFA-BDP dose levels. In 
addition, the mean degree of suppression at 800pgday-’ 
HFA-BDP was not significantly different than at 
800pgday-’ CFC-BDP (95% CI: -2.16, 47.89%). 
Osteocalcin 
Within bone tissue there is a high degree of metabolic 
turnover that reflects the dynamic equilibrium between the 
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FIG. 7. Serum osteocalcin values during a l-year study 
(HFA-BDP vs. CFC-BDP). Source: Ref. 19. -: HFA- 
BDP (200-800 gg day-‘); __ : CFC-BDP (400- 
1600pgday-‘). 
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activity of the bone-forming cells (osteoclasts) and the 
breakdown cells (osteoblasts). Bone loss though long-term 
corticosteroid administration is due to both suppression of 
bone formation and also to increased bone resorption ,(due 
to reduced secretion of sex hormones) together with 
increased parathyroid activity due to reduced calcium 
absorption from the bowel and kidneys. Secretion of serum 
osteocalcin from osteoblasts is thought to be the surrogate 
marker of choice for assessing bone turnover, due to its 
sensitivity, specificity and high degree of reproducibility (16). 
Whilst there are guidelines on the prevention and 
treatment of osteoporosis due to oral corticosteroids (18) 
the relevance to inhaled corticosteroid therapy remains 
uncertain. However, there are very few controlled studies 
that have evaluated the effects of inhaled corticosteroids on 
bone density, and most of these are difficult to interpret 
because of their relatively small size and the presence of 
confounding factors (such as previously administered oral 
corticosteroids). The evidence has been systematically 
reviewed and it would seem prudent to perform at least 
one measurement of bone density in at-risk patients 
receiving high dose inhaled corticosteroid (e.g. postmeno- 
pausal women, patients with high alcohol consumption, 
patients with a familial history of osteoporosis), so as to 
have a baseline measurement against which to assess 
treatment effects (16). 
With regard to HFA-BDP and bone turnover, Prenner 
ef al. (19) compared the effect of CFC-BDP (400- 
1600 pg day- ‘) with HFA-BDP (200-800 pg day-‘) over a 
12 month period (Fig. 7). During this time there was no 
significant effect (as assessed by change from baseline in 
serum osteocalcin) by either beclomethasone formulation, 
suggesting that, in this case at least, the doses of inhaled 
corticosteroid used have, reassuringly, no effect on bone 
turnover. Further longer term studies using bone density 
measurements are required, however, in at-risk groups. 
Summary 
As has been discussed in the previous sections of the 
Supplement, the improved physical characteristics of 
Dose of extrafine 
. HFA-BDP on adults 
800 (a &Y-5 
FIG. 8. Even up to the recommended ose of 800 pg day- ’ 
HFA-BDP (the highest recommended maximum dose), 
there appear to be no clinically relevant systemic side 
effects associated with HFA-BDP. 
HFA-BDP extrafine aerosol spray allow BDP to be 
delivered more efficiently into the large, medium and small 
airways. This improved delivery has allowed the dose of 
HFA-BDP to be reduced compared to CFC-BDP and 
budesonide, whilst maintaining equipotency with flutica- 
sone. However, unlike fluticasone, HFA-BDP does not 
show a propensity for blood or tissue accumulation when 
administered with a 12-h dosing interval. 
Standard tests for assessing effects on the HPA-axis 
indicate that HFA-BDP extrafine aerosol has a favourable 
systemic bioactivity profile. Even up to the recommended 
dose of 800 pg day-’ HFA-BDP (the highest recommended 
maximum dose), there appear to be no clinically relevant 
systemic side effects associated with HFA-BDP (Fig. 8). 
Thus, viewing the data as a whole, it would seem that, 
compared to CFC-BDP and alternative inhaled corticos- 
teroids, HFA-BDP in a dose of up to 800 pg day- ’ exhibits 
a favourable therapeutic ratio. 
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